Klebanoff_Lab
@KlebanoffLab
A translational research lab @MSKCancerCenter focused on the immunobiology and therapeutic potential of genetically engineered #Tcells and #TCRs. Est.2016 @NYC.
🚨🧬💉Everything you wanted to know about TCR therapies* (*but were afraid to ask). Check out our new review in @NatRevDrugDisc 👇. A wonderful collaboration between @KlebanoffLab, @ND_BakerLab, @QuezadaLab, and @ToniRibas12. @MSKCancerCenter @parkerici rdcu.be/dpCtp
Very sad to hear about the passing of Dr. Zelig Eshhar, a maverick scientist who invented a class of chimeric immune receptors that combine antibody specificity with T-cell effector function. Originally called “T-bodies”, Zelig’s discovery would enable the field of CAR therapies.
We, the Weizmann Institute of Science community, deeply mourn the passing of Prof. Zelig Eshhar of the Department of Immunology and Regenerative Biology. Prof. Eshhar was a trailblazing scientist in the field of cancer immunotherapy, a recipient of the Israel Prize in Life…
In the latest issue! Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias dlvr.it/TLcGmQ
So excited to join my esteemed colleague @BernardAFox and an all star cast of speakers at the 40th @sitcancer Annual Meeting to discuss the therapeutic targeting of epitopes resulting from the #darkmatter of the cancer cell genome. Join us this November! #Tcellpower
#SITC25 Science Preview: Join @BernardAFox @ChilesResearch, Christopher A. Klebanoff, MD @MSKCancerCenter, Rom S. Leidner, MD @ChilesResearch, Catherine Wu, MD @DanaFarber to describe novel cancer antigens derived from the dark genome. Browse details: ow.ly/bCJe50W5vE4
🙌🎉🍾Celebrating Fei and his recently accepted paper in @NatureCancer! Grateful to all of our collaborators, co-authors, and excellent peer reviewers @NathanSinghLab, #SaarGill, and @JoshuaBrodyMD. Stay tuned for the final manuscript! @MSKCancerCenter #Tcellpower #NKcellpower
🚨The *second* randomized clinical study to demonstrate significant survival benefit of T cell therapy Vs. standard of care for a relapsed/refractory solid cancer. Here, GEJ/gastric cancer using claudin 18.2 CAR-T. #Tecllpower thelancet.com/action/showPdf…
Tomorrow at #ASCO2025, PICI CEO @DrKarenKnudsen takes center stage to receive ASCO’s Allen S. Lichter Visionary Leader Award. Time: Saturday, May 31, 9:45 AM–12:00 PM CDT | Room N – Hall B1, McCormick Place With more than 300 peer‑reviewed publications and executive leadership…
In a new study published in @CellPressNews, researchers from MSK and @fredhutch show that it may be possible to develop an #immunotherapy-based approach for #AcuteMyeloidLeukemia and #myelodysplastic syndrome. “This is a potential breakthrough,” says Dr. Omar Abdel-Wahab. “We’re…
#FollowFriday Chris Klebanoff is a talented medical oncologist and translational researcher @MSKCancerCenter, who is a leader in novel cell therapies. I also had the pleasure to work with him @theNCI surgery branch. Go give him a follow @KlebanoffLab!
Bravo Eric 🧬🙌!
Congratulations to Eric Smith, MD, PhD, @DanaFarber on receiving the Outstanding New Investigator Award from @ASGCTherapy. Smith will present on advancing CAR T cell therapy for cancer immunotherapy. #ASGCT2025
Encounter with the legendary Tak Mak at the @EACRnews IO meeting in Barcelona 🇪🇸. Among many scientific discoveries, Tak co-discovered the #TCR and defined the function of #CTLA4. He’s also a super fun (and funny) dude. @sitcancer @MSKCancerCenter @parkerici #Tcellpower
MSK physician-scientist @KlebanoffLab talked about all things #neoantigens for the Novel Classes of Human Cancer Rejection Antigens session this morning at #AACR25.
👉Today in @TheLancetOncol: phase I trial of #CISH KO #neoantigen-selected #TIL in GI cancers. Proud to have worked in collaboration with @cancerassassin1, the Webber/Moriarity labs @UMNCancer, and #IntimaBioscience from pre-clinical->IND->first-in-human. authors.elsevier.com/c/1l0Jr_XRRTs9…
🚨🧬Everything you wanted to know about actionable #neoantigens resulting from cancer mutations besides point mutations (*but were afraid to ask). Join us at 10:15 in 📍Room E351 - McCormick Lakeside Center (Level 3)! @MSKCancerCenter @UCSFCancer @institut_curie
Join cellular therapist & early drug development specialist Dr. Christopher Klebanoff (@KlebanoffLab) for a symposium titled “Therapeutic targeting of public neoantigens resulting from recurrent gene fusions and mRNA mis-splicing events” today at #AACR25 (@AACR). Learn more:…
Bravo @GormallyMDPHD 🙌🧬🥼!
Happening now: MSK research fellow @GormallyMDPHD presents results from a real-world analysis evaluating HLA LOH frequencies and survival outcomes in #cancer at #AACR25.
Join Session Chair and CRI Investigator Dr. Klebanoff @MSKCancerCenter at 10:15 AM today for #AACR's SY16 - Novel Classes of Human Cancer Rejection Antigens: Beyond Point Mutations, and hear from Dr. Okada @UCSF and Dr. Amigorena of Institut Curie. More: bit.ly/4jlEJgE
Research fellow @GormallyMDPHD will present results of a real-world analysis that evaluated HLA LOH frequencies & survival outcomes in cancer. @MSKCancerCenter @AACR #AACR25 Learn more: bit.ly/44Ij39Y Session starts at 2:30 p.m. CT | Presentation at 3:05 p.m. CT
🚨Today in @CellCellPress, we show that RNA splicing factor mutations in myeloid cancers generate splicing-derived public neoantigens targetable by #TCR tx. Amazing collaboration co-led by @AbdelWahablab, @bradleybio, and @KlebanoffLab. #Tcellpower cell.com/cell/fulltext/…
Klebanoff Lab's "Physician-Scientist Action Hero." Mad scientist playset sold separately. *Batteries not included. chatgpt.com/s/m_6801711d79….
